The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China.

Background: The KEYNOTE-048 and KEYNOTE-040 study have demonstrated the efficacy of pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC), we conducted this real-world study to investigate the efficacy of pembrolizumab in patients with R/M HNSCC.

Methods: This is a single-center retrospective study conducted in the Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Shanghai, China). Between December 2020 and December 2022, a total of 77 patients with R/M HNSCC were included into analysis.

The Illicit Supply of New Psychoactive Substances Within and From China: A Descriptive Analysis.

Although China has played a significant role in the emergence and expansion of new psychoactive substances (NPS) worldwide, little research has specifically focused on the illicit supply of NPS within China and smuggling from China. In this study, data were extracted from sentencing files obtained from closed criminal cases to develop an objective understanding of the NPS supply chain in China. The sample consisted of 341 major cases concerning the illicit supply of three groups of NPS (ketamine, synthetic cathinone, and fentanyl) and five categories of offense, including manufacturing, distributing, retailing, transporting, and manufacturing-retailing.